Nasus Pharma Ltd.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dan Teleman
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Yigal Alon 65 Tel Aviv Israel 6744317
- IPO Date
- Aug 13, 2025
- CIK
- 0002029039
- Website
- nasuspharma.com
- Similar Companies
- Business
- Nasus Pharma Ltd. (NSRX) operates as a clinical-stage specialty pharmaceutical company focused on developing innovative powder-based intranasal drugs utilizing proprietary microsphere technology to address acute emergency medical conditions and public health threats, including anaphylactic shock and opioid overdose; its lead product candidates include NS002, an intranasal epinephrine powder nasal spray in phase 2 for treating severe allergic reactions, and NS001, an intranasal naloxone powder nasal spray that has completed pivotal phase 3 studies for opioid overdose reversal; the platform also encompasses additional preclinical proof-of-concept programs targeting rapid drug absorption advantages, demonstrated in clinical studies as seven times higher absorption in the first four minutes and four times higher in the first ten minutes compared to liquid formulations. Founded in May 2019 by Udi Gilboa and Dalia Megiddo and headquartered at Yigal Alon 65 in Tel Aviv, Israel, the company conducts its research, development, and clinical activities primarily from Israel with global regulatory ambitions including FDA and EMA submissions. In October 2025, Nasus Pharma executed comprehensive agreements with Aptar France S.A.S. and AptarGroup Inc., a leading global drug delivery systems manufacturer, to provide end-to-end development support, validated unit-dose technology, manufacturing infrastructure, and supply chain capabilities for advancing NS002 through clinical trials and commercialization, accelerating market entry while leveraging Aptar's established regulatory pathways; the company completed its initial public offering in August 2025, raising $10 million on the NYSE American exchange.
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
Nasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript
What's Going On With Nasus Pharma Stock On Wednesday
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Nasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
Nasus Pharma Announces Closing of $15.0 Million Private Placement
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Nasus Pharma CEO Issues 2025 Letter to Shareholders
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference